GP6 and rheumatoid arthritis: In one study, PLGA NPs containing the drug FK506 (a model drug for RA' therapy) were coated with platelet‐membranes with the intent of platelet membrane proteins (GPVI) interacting with overexpressed CD44 and collagen IV in synovial tissues to facilitate local accumulation and drug release.79